Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
60.4M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
59.9M
-
Shares change
-
+7.89M
-
Total reported value, excl. options
-
$1.39B
-
Value change
-
+$172M
-
Put/Call ratio
-
0.49
-
Number of buys
-
86
-
Number of sells
-
-41
-
Price
-
$23.28
Significant Holders of Spyre Therapeutics, Inc. - Common Stock (SYRE) as of Q4 2024
153 filings reported holding SYRE - Spyre Therapeutics, Inc. - Common Stock as of Q4 2024.
Spyre Therapeutics, Inc. - Common Stock (SYRE) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59.9M shares
of 60.4M outstanding shares and own 99.2% of the company stock.
Largest 10 shareholders include FMR LLC (8.8M shares), Fairmount Funds Management LLC (4.02M shares), RTW INVESTMENTS, LP (3.62M shares), BlackRock, Inc. (3.4M shares), VANGUARD GROUP INC (2.85M shares), Driehaus Capital Management LLC (2.8M shares), VR Adviser, LLC (2.69M shares), BRAIDWELL LP (2.58M shares), PERCEPTIVE ADVISORS LLC (2.57M shares), and COMMODORE CAPITAL LP (1.99M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.